These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 15280474

  • 1. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [Abstract] [Full Text] [Related]

  • 2. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [Abstract] [Full Text] [Related]

  • 3. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
    Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H.
    J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
    Habashita H, Kokubo M, Hamano S, Hamanaka N, Toda M, Shibayama S, Tada H, Sagawa K, Fukushima D, Maeda K, Mitsuya H.
    J Med Chem; 2006 Jul 13; 49(14):4140-52. PubMed ID: 16821774
    [Abstract] [Full Text] [Related]

  • 5. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.
    Virology; 2005 Jul 20; 338(1):182-99. PubMed ID: 15935415
    [Abstract] [Full Text] [Related]

  • 6. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM, Wang ZX, Trent JO, Murray JL, Hu QX, DeLeeuw L, Moore PS, Chang Y, Peiper SC.
    J Mol Biol; 2001 Nov 09; 313(5):1181-93. PubMed ID: 11700073
    [Abstract] [Full Text] [Related]

  • 7. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
    Wang FY, He SY, Zhang ZJ, He LF, Chen XW, Teng T.
    AIDS Res Hum Retroviruses; 2011 Oct 09; 27(10):1111-5. PubMed ID: 21375388
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
    Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M.
    Antimicrob Agents Chemother; 2001 Dec 09; 45(12):3538-43. PubMed ID: 11709336
    [Abstract] [Full Text] [Related]

  • 9. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.
    J Pharmacol Exp Ther; 2011 Jul 09; 338(1):228-39. PubMed ID: 21459966
    [Abstract] [Full Text] [Related]

  • 10. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
    Aquaro S, Menten P, Struyf S, Proost P, Van Damme J, De Clercq E, Schols D.
    J Virol; 2001 May 09; 75(9):4402-6. PubMed ID: 11287590
    [Abstract] [Full Text] [Related]

  • 11. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M.
    Mol Pharmacol; 2008 Mar 09; 73(3):789-800. PubMed ID: 18096812
    [Abstract] [Full Text] [Related]

  • 12. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
    Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, Baba M.
    Antimicrob Agents Chemother; 2005 Aug 09; 49(8):3474-82. PubMed ID: 16048963
    [Abstract] [Full Text] [Related]

  • 13. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
    Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K, Miyakawa T, Aoki M, Fukushima D, Mitsuya H.
    J Biol Chem; 2001 Sep 14; 276(37):35194-200. PubMed ID: 11454872
    [Abstract] [Full Text] [Related]

  • 14. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T, Hoveyda H, Ooms F, Schols D, Bernard J, Fraser G.
    J Pharmacol Exp Ther; 2011 Jun 14; 337(3):655-62. PubMed ID: 21389095
    [Abstract] [Full Text] [Related]

  • 15. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.
    Nardese V, Longhi R, Polo S, Sironi F, Arcelloni C, Paroni R, DeSantis C, Sarmientos P, Rizzi M, Bolognesi M, Pavone V, Lusso P.
    Nat Struct Biol; 2001 Jul 14; 8(7):611-5. PubMed ID: 11427892
    [Abstract] [Full Text] [Related]

  • 16. Monocyte chemoattractant protein-2 (CC chemokine ligand 8) inhibits replication of human immunodeficiency virus type 1 via CC chemokine receptor 5.
    Yang OO, Garcia-Zepeda EA, Walker BD, Luster AD.
    J Infect Dis; 2002 Apr 15; 185(8):1174-8. PubMed ID: 11930329
    [Abstract] [Full Text] [Related]

  • 17. I-TAC/CXCL11 is a natural antagonist for CCR5.
    Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B.
    J Leukoc Biol; 2004 Sep 15; 76(3):701-8. PubMed ID: 15178708
    [Abstract] [Full Text] [Related]

  • 18. CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells.
    Ruffing N, Sullivan N, Sharmeen L, Sodroski J, Wu L.
    Cell Immunol; 1998 Nov 01; 189(2):160-8. PubMed ID: 9790730
    [Abstract] [Full Text] [Related]

  • 19. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.
    Szabo I, Wetzel MA, Zhang N, Steele AD, Kaminsky DE, Chen C, Liu-Chen LY, Bednar F, Henderson EE, Howard OM, Oppenheim JJ, Rogers TJ.
    J Leukoc Biol; 2003 Dec 01; 74(6):1074-82. PubMed ID: 12972507
    [Abstract] [Full Text] [Related]

  • 20. Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope.
    Staudinger R, Wang X, Bandrés JC.
    Biochem Biophys Res Commun; 2001 Aug 10; 286(1):41-7. PubMed ID: 11485305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.